CARM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CARM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CARISMA Therapeutics's share price for the quarter that ended in Mar. 2024 was $2.27. CARISMA Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 41.54 Mil. Therefore, CARISMA Therapeutics's market cap for the quarter that ended in Mar. 2024 was $94.30 Mil.
CARISMA Therapeutics's quarterly market cap declined from Sep. 2023 ($170.49 Mil) to Dec. 2023 ($118.99 Mil) and declined from Dec. 2023 ($118.99 Mil) to Mar. 2024 ($94.30 Mil).
CARISMA Therapeutics's annual market cap stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($118.99 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CARISMA Therapeutics's Enterprise Value for Today is $4.98 Mil.
The historical data trend for CARISMA Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Market Cap | - | - | - | 118.99 |
CARISMA Therapeutics Quarterly Data | ||||||||||||
Dec20 | Jun21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Market Cap | Get a 7-Day Free Trial | 124.79 | 353.16 | 170.49 | 118.99 | 94.30 |
For the Biotechnology subindustry, CARISMA Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CARISMA Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $2.93 | * | 40.6099 | |
= | $118.99 |
CARISMA Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as
Market Cap (Q: Mar. 2024 ) | = | Share Price (Q: Mar. 2024 ) | * | Shares Outstanding (EOP) (Q: Mar. 2024 ) |
= | $2.27 | * | 41.5427 | |
= | $94.30 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics (NAS:CARM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of CARISMA Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Modernatx, Inc. | 10 percent owner | 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Steven Kelly | director, officer: President and CEO | C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Briggs Morrison | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451 |
Richard Steven Morris | officer: Chief Financial Officer | 397 EAGLEVIEW BOULEVARD, EXTON PA 19341 |
Chidozie Ugwumba | director | 158 FILMORE STREET, DENVER CO 80206 |
Michael Klichinsky | officer: Chief Scientific Officer | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Michael Torok | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Regina Hodits | director | C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104 |
Bjorn Odlander | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
Minori Rosales | officer: Chief Development Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Jewett Michael A. S. | director | C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Peter Honig | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Patricia M. Drake | officer: Chief Commercial Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
Elly Ryu | officer: Principal Accounting Officer | 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142 |
From GuruFocus
By PRNewswire • 12-21-2023
By PRNewswire • 06-28-2023
By PRNewswire • 11-28-2023
By PRNewswire PRNewswire • 05-08-2023
By PRNewswire • 09-05-2023
By PRNewswire • 12-14-2023
By PRNewswire PRNewswire • 05-30-2023
By PRNewswire • 08-24-2023
By PRNewswire • 11-22-2023
By PRNewswire • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.